© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer
Affiliations of authors: Department of Internal Medicine, Division of Molecular Medicine and Genetics (BLN, JDB, LPT, SBG), Department of Epidemiology, School of Public Health (BLN, SBG), and Department of Human Genetics (SBG), University of Michigan Medical School, Ann Arbor, MI; Department of Community Medicine and Epidemiology, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel (GR); Clalit Health Services National Cancer Control Center, Haifa (GR, RA).
Correspondence to: Stephen B. Gruber, MD, PhD, MPH, Division of Molecular Medicine and Genetics, 4301 MSRB III, Box 0638, 1150 W. Medical Center Dr., University of Michigan, Ann Arbor, MI 48109-0638 (e-mail: sgruber{at}umich.edu)
Background: Mutations in BRCA1 and/or BRCA2 (BRCA1/2) profoundly increase the risks of breast and ovarian cancers, but it is unclear whether mutations in these genes increase the risk of colorectal cancer. We investigated BRCA1/2 founder mutations and a family history of breast cancer as potential risk factors for colorectal cancer. Methods: In the population-based Molecular Epidemiology of Colorectal Cancer study in northern Israel, 1422 case patients with incident colorectal cancer, diagnosed between March 31, 1998, and December 31, 2002, and 1566 control subjects without colorectal cancer were genotyped for the BRCA1 187delAG, BRCA1 5385insC, and BRCA2 6174delT founder mutations. Genotypes and interview data from all case patients and control subjects and from only those of Ashkenazi Jewish descent (1002 case patients and 1038 control subjects) were used to calculate odds ratios [ORs] from logistic regression. Results: Twenty-four (2.4%) case patients and 20 (1.9%) control subjects carried one of the three mutations (OR = 1.24, 95% confidence interval [CI] = 0.68 to 2.26). A family history of breast cancer in a female relative was not associated with an increased risk of colorectal cancer, even after adjustment for the presence of a BRCA founder mutation (OR = 1.03, 95% CI = 0.75 to 1.41). Conclusions: Although weak associations cannot be excluded, Ashkenazi BRCA founder mutations do not confer a strongly elevated risk of colorectal cancer. Similarly, a family history of breast cancer does not appear to be a strong risk factor for colorectal cancer in this population.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer
- Bernard Friedenson
J Natl Cancer Inst 2004 96: 1184-1185.[Extract] [Full Text] [PDF]
- RESPONSE: Re: BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer
- Bethany L. Niell, Gad Rennert, Joseph D. Bonner, and Stephen B. Gruber
J Natl Cancer Inst 2004 96: 1185-1186.[Extract] [Full Text] [PDF]
Editorial about this Article
- One Less Thing to Worry About: The Shrinking Spectrum of Tumors in BRCA Founder Mutation Carriers
- Judy E. Garber and Sapna Syngal
J Natl Cancer Inst 2004 96: 2-3.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  F. H. Vaz, P. M. Machado, R. D. Brandao, C. T. Laranjeira, J. S. Eugenio, A. H. Fernandes, and S. P. Andre Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients J. Histochem. Cytochem., November 1, 2007; 55(11): 1105 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kadouri, A. Hubert, Y. Rotenberg, T. Hamburger, M. Sagi, C. Nechushtan, D. Abeliovich, and T. Peretz Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations J. Med. Genet., July 1, 2007; 44(7): 467 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Grabsch, M. Dattani, L. Barker, N. Maughan, K. Maude, O. Hansen, H. E. Gabbert, P. Quirke, and W. Mueller Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1494 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C J van Asperen, R M Brohet, E J Meijers-Heijboer, N Hoogerbrugge, S Verhoef, H F A Vasen, M G E M Ausems, F H Menko, E B Gomez Garcia, J G M Klijn, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary J. Med. Genet., September 1, 2005; 42(9): 711 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Rozek, S. M. Lipkin, E. R. Fearon, S. Hanash, T. J. Giordano, J. K. Greenson, R. Kuick, D. E. Misek, J. M.G. Taylor, J. A. Douglas, et al. CDX2 Polymorphisms, RNA Expression, and Risk of Colorectal Cancer Cancer Res., July 1, 2005; 65(13): 5488 - 5492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Friedenson Re: BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1184 - 1185. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Niell, G. Rennert, J. D. Bonner, and S. B. Gruber RESPONSE: Re: BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1185 - 1186. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Garber and S. Syngal One Less Thing to Worry About: The Shrinking Spectrum of Tumors in BRCA Founder Mutation Carriers J Natl Cancer Inst, January 7, 2004; 96(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
|
|
T. Kirchhoff, J. M. Satagopan, N. D. Kauff, H. Huang, P. Kolachana, C. Palmer, H. Rapaport, K. Nafa, N. A. Ellis, and K. Offit Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer J Natl Cancer Inst, January 7, 2004; 96(1): 68 - 70. [Abstract] [Full Text] [PDF]
|
|